Profile: PDL BioPharma Inc (PDLI.O)
19 Jul 2019
PDL BioPharma, Inc., incorporated on July 24, 1986, seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. The Company is focused on the acquisition of additional products, and expects to transact royalty transactions and debt transactions.
The Company holds the worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT in the rest of the world. Tekturna (or Rasilez outside the United States) contains aliskiren, a direct renin inhibitor, for the treatment of hypertension. Tekturna HCT (or Rasilez HCT outside the United States) is a combination of aliskiren and hydrochlorothiazide, a diuretic, for the treatment of hypertension in patients not controlled by monotherapy and as an initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. It is not indicated for use with angiotensin-converting enzyme (ACEs) and angiotensin II receptor blockers (ARBs) in-patient with diabetes or renal impairment and not for use in patients with known anuria or hypersensitivity to sulfonamide-derived drugs.
Income Generating Assets
The Company acquires income-generating assets. These income-generating assets are typically in the form of notes receivables, royalty rights and hybrid notes/royalties receivable and in some cases, equity. The Company primarily focuses its income generating asset acquisition strategy on commercial-stage therapies and medical devices having economic fundamentals. The Company receives royalty revenue from a product under the Queen et al. patent licenses, Tysabri. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
PDL BioPharma Inc
932 Southwood Blvd
INCLINE VILLAGE NV 89451